CClinicalTrials.gg
CompletedNCT06699303dermatitUpdated Mar 11, 2025

Effect of Breast Milk on Diaper Dermatitis in Infants

An interventional study of Use of diaper rash cream containing Hamamelis virginiana (potency 12mg/100g) 5.35 g / 100 g for infants in the control group in diaper dermatitis care in Diaper Dermatitis, sponsored by Sakarya University. Completed at 2 sites in Turkey. Open to participants aged 1 Month to 6 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-11.

Sponsored by Sakarya University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled May 2023, registered Dec 2023).
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
1 Month to 6 Months
Sex
All
01

Study summary

Diaper dermatitis, one of infants' most common health problems, can be treated with various methods. One of these methods is breast milk. Studies show that breast milk is a non-harmful, accessible and effective product in the healing of dermatitis. This study was planned to be a randomized, controlled, and single-blinded study to evaluate the effect of breast milk and diaper rash cream containing Hamamelis virginiana (potency 12mg/100g) 5.35 g/100g on the healing process in 0-12-month-old infants with diaper dermatitis. The population of the study consisted of 0-12 months old infants with diaper dermatitis who applied to the Pediatrics Outpatient Clinic of X Hospital. Since not all infants with diaper dermatitis complaints were examined, the number of the population cannot be known. The sample size was calculated as 26 for each group and 52 in total . 30 infants were planned to be included in each group. The licensed IBM SPSS 22.0 (Statistical Package for the Social Sciences) package program will be used for statistical data analysis. Standard deviation, number and percentage will be used in data analysis. Man Whitney U test and Fisher exact test (repeated measures) will be used to evaluate whether there is a difference between independent groups. For the significance level of the data, 0.05 will be used.

Read the detailed description

Diaper dermatitis, one of the most common health problems in infants, can be treated with various methods (Blume-Peytavi Kanti, 2018; Gozen et al., 2014; Seifi, Jalali, Heidari, 2017). One of these methods is breast milk. Breast milk has strong immunologic properties that protect infants from respiratory diseases, middle ear infections and gastrointestinal system diseases. It also has protective effects against diabetes mellitus, obesity, hyperlipidemia, hypertension, cardiovascular diseases, autoimmunity and asthma. Because of these positive properties, breast milk has lifelong positive effects. In recent years, studies on the effect of breast milk in the treatment of dermatitis have been increasing (Kasrae, Farahani, Yousefi, 2015, Blume-Peytavi Kanti, 2018; Gozen et al., 2014; Seifi, Jalali, Heidari, 2017, Bener et al., 2007). In a study conducted by Gozen et al. using breast milk and barrier cream, barrier cream was found to be more effective than breast milk, especially in the treatment of moderate and severe dermatitis (Gozen et al., 2014). Farahani et al. applied 1% hydrocortisol and breast milk for 7 days in a randomized controlled study on diaper dermatitis. In this study, improvement was found to be similar on the 3rd and 7th days of treatment and it was concluded that breast milk was safe and effective (Farahani, Ghobadzadeh, Yousefi, 2013) Seifi et al. found a statistically significant difference between the groups in favor of breast milk in terms of skin rash score on the first and third days of the application in their study using breast milk in diaper rash care (p=0.013, p=0.005, respectively). This difference was even more significant on the fifth day (p=0.004, p=0.001) (Seifi et al., 2017). Studies show that breast milk is a non-harmful, free and effective product for the healing of dermatitis.

This study was planned to be a randomized, controlled, and single-blinded study to evaluate the effect of breast milk and diaper rash cream containing Hamamelis virginiana (potency 12mg/100g) 5.35 g/100g on the healing process in 0-12-month-old infants with diaper dermatitis. The population of the study consisted of 0-12 months old infants with diaper dermatitis who applied to the Pediatrics Outpatient Clinic . Since not all infants with diaper dermatitis complaints were examined, the number of the population cannot be known. The sample size was calculated as 26 for each group and 52 in total with the "A priori. 30 infants were planned to be included in each group. The licensed IBM SPSS 22.0 (Statistical Package for the Social Sciences) package program will be used for statistical data analysis. Standard deviation, number and percentage will be used in data analysis. Man Whitney U test and Fisher exact test (repeated measures) will be used to evaluate whether there is a difference between independent groups. For the significance level of the data, 0.05 will be used.

02

Conditions studied

  • Diaper Dermatitis

Keywords

  • diaper dermatitis
  • mother's milk
  • hamamelı̇s vı̇rgı̇nı̇nana
03

In context

Dermatitis

1,435 studies on the registry are indexed under Dermatitis; 131 are open to participants now.

This study's enrollment of 30 is below the median of 64 across 1,131 interventional studies indexed under Dermatitis.

Browse Dermatitis studies →

Lead sponsor

Sakarya University is the lead sponsor of 178 studies on the registry; 48 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Month to 6 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Babies fed with breast milk,
  • Healthy babies aged 0-6 months,
  • Babies who do not have diarrhea or thrush at the time of application,
  • Fungus, eczema, allergic disease, etc.Babies without a history of skin disease,
  • Babies who do not use antimycotic drugs (Ampotericin etc.), antibiotics and steriods ---before and during the application,
  • Babies who do not apply medication or other materials (barrier creams, powder and other medications) to the dermatitis area.

Exclusion criteria

Exclusion Criteria:

  • Babies who are not breastfed
  • Those who did not agree to participate in the study
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Uncomplicated Diaper Dermatitis Severity Assessment Scale in Babies

    In the study, a data collection form consisting of 13 questions regarding the sociodemographic characteristics of 0-12 month old babies and the "Uncomplicated Diaper Dermatitis Severity Assessment Scale in Babies, developed by Buckley et al. in 2016 and whose Turkish validity and reliability studies were conducted by Keskin, will be used.

    Other: Use of diaper rash cream containing Hamamelis virginiana (potency 12mg/100g) 5.35 g / 100 g for infants in the control group in diaper dermatitis care

Interventions

  • OtherUse of diaper rash cream containing Hamamelis virginiana (potency 12mg/100g) 5.35 g / 100 g for infants in the control group in diaper dermatitis care

    In diaper dermatitis care, it was planned to use their mothers' milk for the babies in the experimental group and diaper rash cream containing Hamamelis virginiana (potency 12mg/100g) 5.35 g/100g for the babies in the control group. The reason why diaper rash cream containing Hamamelis virginiana (potency 12mg/100g) 5.35 g/100 g is preferred is that it is the most frequently used cream in cases of uncomplicated diaper dermatitis. The mothers of the babies in the control group will be asked to wash and dry the baby's diaper with soap and water during each diaper change and then apply diaper rash cream containing Hamamelis virginiana (potency 12mg/100g) 5.35 g/100 g. Mothers will be asked to record any new signs and symptoms that develop during the treatment and to inform the investigators will be asked to provide information. Positive and negative effects of treatment will also be recorded.

    Also known as: Administration of mother's milk for infants in the experimental group in the care of diaper dermatitis

06

What researchers measure

Primary outcomes

  1. It will be evaluated whether there is a difference between breast milk and dermatitis cream in terms of healing diaper dermatitis in babies aged 0-12 months.

    Data will be collected using the baby identification form and the Infant Uncomplicated Diaper Dermatitis Severity Rating Scale (UCDAS).

    Time frame: 6 months

07

Study locations

2 sites
  • Sakarya Training and Research Hospital
    Sakarya, Adapzarı 54100, Turkey
  • Sakarya Üniversitesi
    Sakarya, Adapzarı 54100, Turkey
08

References and documents

Individual participant data

Plan to share: No — Our study findings have not yet been published.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06699303
Lead sponsor
Sakarya University
Responsible party
Sponsor
First posted
Nov 21, 2024
Start date
May 1, 2023
Primary completion
Jan 18, 2024
Completion
May 10, 2024
Last update
Mar 11, 2025

Study contacts

Döndü 1 Sevimli Güler, PhD
principal investigator · Sakarya Training and Research Hospital
Zekiye 4 Turan, PhD
study director · Sakarya University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion